These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23090983)

  • 1. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.
    Yan W; Zhang W; You G; Zhang J; Han L; Bao Z; Wang Y; Liu Y; Jiang C; Kang C; You Y; Jiang T
    Neuro Oncol; 2012 Dec; 14(12):1432-40. PubMed ID: 23090983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH clonal heterogeneity segregates a subgroup of non-1p/19q codeleted gliomas with unfavourable clinical outcome.
    Luo S; Zhu S; Liao J; Zhang Y; Hou X; Luo T; Zhao E; Xu J; Pang L; Liang X; Xiao Y; Li X
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):394-405. PubMed ID: 33098109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.
    Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ
    Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
    Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
    Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases.
    Lin N; Yan W; Gao K; Wang Y; Zhang J; You Y
    PLoS One; 2014; 9(4):e94871. PubMed ID: 24755548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
    Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
    PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes.
    Li A; Walling J; Ahn S; Kotliarov Y; Su Q; Quezado M; Oberholtzer JC; Park J; Zenklusen JC; Fine HA
    Cancer Res; 2009 Mar; 69(5):2091-9. PubMed ID: 19244127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ
    J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
    Wang H; Jiang C
    Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.
    Gravendeel LA; Kouwenhoven MC; Gevaert O; de Rooi JJ; Stubbs AP; Duijm JE; Daemen A; Bleeker FE; Bralten LB; Kloosterhof NK; De Moor B; Eilers PH; van der Spek PJ; Kros JM; Sillevis Smitt PA; van den Bent MJ; French PJ
    Cancer Res; 2009 Dec; 69(23):9065-72. PubMed ID: 19920198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
    Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
    Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
    Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
    Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular classification of low-grade diffuse gliomas.
    Kim YH; Nobusawa S; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Vital A; Mariani L; Stawski R; Watanabe T; De Girolami U; Kleihues P; Ohgaki H
    Am J Pathol; 2010 Dec; 177(6):2708-14. PubMed ID: 21075857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.